RIPK1 and Alzheimer disease: RIPK1 inhibition has emerged as a prime target in various neurodegenerative disorders, including AD, PD, and HD (Degterev, Ofengeim & Yuan, 2019; Li & Yuan, 2023; Xu, Zhang & Zhuang, 2023).